NASDAQ:QLGN Qualigen Therapeutics (QLGN) Stock Price, News & Analysis $1.13 +0.13 (+13.00%) As of 10/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsNews and TrendsSEC Filings About Qualigen Therapeutics Stock (NASDAQ:QLGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Qualigen Therapeutics alerts:Sign Up Key Stats Today's Range$0.99▼$1.2450-Day Range$0.68▼$1.8052-Week Range$1.61▼$8.81Volume472,899 shsAverage Volume1.52 million shsMarket Capitalization$1.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused primarily on developing therapies for cancer and other serious diseases. The company’s lead therapeutic program is QN-302, a small-molecule drug candidate being investigated for its potential to treat solid tumors, including pancreatic cancer. Qualigen is also developing additional oncology-focused programs, including QN-247, an aptamer-based candidate designed to target nucleolin, a protein associated with cancer-cell growth and survival. These programs remain subject to clinical and regulatory development, and their ultimate safety and effectiveness have not been established. The company traces its history to Qualigen, Inc., a developer of diagnostic products and instruments. Through its wholly owned subsidiary, Qualigen continues to support diagnostic activities involving the FastPack system, an automated platform used with certain clinical laboratory tests. Qualigen Therapeutics is headquartered in San Diego, California, and its operations are directed toward biotechnology research, clinical development and diagnostic products serving healthcare markets.AI Generated. May Contain Errors. Read More Receive QLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Qualigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QLGN Stock News HeadlinesQualigen Therapeutics Signs Exclusive License Agreement with the University of Louisville, Plans to Develop AS1411 for the Treatment of COVID-19December 13, 2025 | cnn.comQualigen Therapeutics Rebrands to AIxCrypto HoldingsNovember 17, 2025 | msn.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.October 26 at 1:00 AM | Weiss Ratings (Ad)Qualigen Therapeutics stockholders approve all proposals with majority voteNovember 17, 2025 | msn.comFaraday Future Becomes Majority Shareholder in Qualigen Therapeutics, Preparing for Corporate Rebranding and Strategic Transformation on November 20November 16, 2025 | quiverquant.comQQualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 StrategyNovember 16, 2025 | globenewswire.comQualigen Therapeutics to rebrand as AIxCryptoOctober 28, 2025 | msn.comQualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025October 27, 2025 | globenewswire.comSee More Headlines QLGN Stock Analysis - Frequently Asked Questions How have QLGN shares performed this year? Qualigen Therapeutics' stock was trading at $2.34 at the beginning of the year. Since then, QLGN stock has decreased by 51.7% and is now trading at $1.13. How were Qualigen Therapeutics' earnings last quarter? Qualigen Therapeutics, Inc. (NASDAQ:QLGN) issued its quarterly earnings results on Friday, November, 14th. The company reported ($4.68) earnings per share (EPS) for the quarter. When did Qualigen Therapeutics' stock split? Qualigen Therapeutics shares reverse split before market open on Tuesday, November 5th 2024.The 1-50 reverse split was announced on Friday, November 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did Qualigen Therapeutics IPO? Qualigen Therapeutics (QLGN) raised $44 million in an initial public offering (IPO) on Friday, June 19th 2015. The company issued 4,000,000 shares at $10.00-$12.00 per share. How do I buy shares of Qualigen Therapeutics? Shares of QLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Qualigen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Qualigen Therapeutics investors own include NIO (NIO), AMC Entertainment (AMC), Vaxart (VXRT), FuelCell Energy (FCEL), Ideanomics (IDEX), Ocugen (OCGN) and Seanergy Maritime (SHIP). Company Calendar Last Earnings11/14/2025Today10/26/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Software Sub-IndustryApplication Software Current SymbolNASDAQ:QLGN CIK1460702 Webwww.qualigeninc.com Phone(760) 918-9165FaxN/AEmployees50Year Founded1996Profitability EPS (Trailing Twelve Months)($7.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.26 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-202.16% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.12) per share Price / Book-0.27Miscellaneous Outstanding Shares1,695,000Free Float1,664,000Market Cap$1.92 million OptionableNot Optionable Beta0.24 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:QLGN) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredAnd they say the headline number understates what’s really happening.Goldman Sachs just admitted it underestimated central bank gold purchases by more than 500 percent, with buyin...Cedar Gold Group | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
